| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Rivus Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $224.04M | Series B-2 | 1/16/2025 | $122.98M | $506.82M | $4.76 | RA Capital Management, Bain Capital, BB Biotech AG, Longitutde Capital, Medicxi, RxCapital | ||||
 | SafeTraces | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | ShapeTX | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $249.61M | Series C-1 | 1/7/2025 | $91.03M | $333.34M | $0.41 | Undisclosed Investors | ||||
 | Stipple Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $121.65M | Series A | 4/6/2026 | $100.2M | $230.09M | $26.47 | RA Capital, Andreessen Horowitz, Nextech Invest, Emerson Collective, GV, LoLa Capital Partners, GordonMD Global Investments | ||||
 | Totus Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | TriGemX Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $573.45M | Series E | 10/1/2026 | $93.99M | $341.19M | $0.79 | The Column Group, TCGX, Viking Global Investors | ||||
 | Vizgen | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $291.78M | Series E-1 | 1/8/2026 | $41.95M | $171.95M | $0.12 | ARCH Venture Partners, M Ventures, Northpond Ventures | ||||
 | Zetagen Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | 4D Molecular Therapeutics (4DMT) | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | 908 Devices | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Abcuro | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $353.25M | Series D-1 | 8/18/2026 | $32.35M | $120.99M | $0.60 | New Leaf Venture Partners, Rock Springs Capital, Abrdn, Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, New Enterprise Associates, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, ShangBay Capital | ||||
 | Accutar Biotechnology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $207.47M | Series B+4 | 8/20/2021 | $80M | $987.52M | $77.58 | Undisclosed Investors | ||||
 | Aktis Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Applied StemCell | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Aragen Life Sciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Aviceda Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | C4 Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | CG Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $510.76M | Series F | 8/2/2023 | $105.02M | $615.24M | $1.29 | Foresite Capital, TCGX, Avidity Partners, BVF Partners, Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporatoin, RA Capital Management | ||||
 | Endeavor BioMedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $295.58M | Series C | 4/24/2024 | $132.58M | $676.04M | $6.52 | AyurMaya, Fidelity Management & Research Company, Invus, SymBiosis, Velosity Capital, Woodline Partners, Abrdn Inc, Ally Bridge Group, Avidity Partners, Eckuity Capital, Longitude Capital, Omega Funds, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch Bio, T. Rowe Price Associates | ||||
 | GenapSys | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $201.18M | Series D | 5/27/2021 | $70M | $463.55M | $7.84 | Farallon Capital Management, Soleus Capital | ||||
 | Hexagon Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $256.56M | Series C | 10/23/2026 | $48.39M | $128.63M | $0.57 | The Column Group, Nextech Invest, Deviation Capital, 8VC, CPP Investments | ||||
 | Kardigan | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $607.17M | Series B-1 | 10/14/2025 | $80.78M | $1.6B | $21.37 | Fidelity, T. Rowe Price, ARCH Venture Partners, Sequoia Heritage | ||||
 | LinusBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Matchpoint Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250M | Series B-1 | 10/7/2026 | $122.23M | $272.56M | $0.51 | Nextech Invest, Norwest, Invus, BB Biotech, T1D Fund, BOLD Longevity Growth, Access Biotechnology, Atlas Venture, Sanofi Ventures, Digitalis Ventures, Vertex Ventures HC, Alexandria Venture Investments, Binney Street Capital | ||||